A Phase 3 interventional study of ezetimibe (+) simvastatin and Comparator: atorvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 8th largest by enrollment of the 97 interventional ones that give a count, is one of 16 that started in 2007, is one of 50 in phase 3, and was the 24th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 16 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 786 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 15th largest by enrollment of the 81 interventional ones that give a count, is one of 13 that started in 2007, is one of 58 in phase 3, and was the 38th registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the percentage of patients with either established cardiovascular disease (CVD), at "high risk" of developing CVD or with diabetes who are on simvastatin 40mg, with fasting LDL-C > 2mmol/l, who are able to attain the recommended LDL-C target of \< 2mmol/l following 6 weeks treatment with either ezetimibe/simvastatin 10/40mg, atorvastatin 40mg or rosuvastatin 10mg.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm 1: Drug
Drug: ezetimibe (+) simvastatin
Arm 2: Active comparator
Drug: Comparator: atorvastatin
Arm 3: Active comparator
Drug: Comparator: rosuvastatin
Drug pages: Ezetimibe · Simvastatin
ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally, cholesterol lowering medication.
Also known as: MK0653A
atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally
Also known as: atorvastatin
rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally.
Also known as: rosuvastatin
Percentage of Patients Achieving a Target of Fasting LDL-C of <2mmol/l at Study End
Fasting LDL-C was the primary efficacy variable. The primary efficacy analysis was based on the proportion of patients achieving a target of \<2mmol/l in fasting LDL-C at study end.
Time frame: 6 Weeks
Patients with diabetes, cardiovascular disease (CVD) or a "high risk" of developing CVD and a fasting LDL-C level of ≥2mmol/l, having been on simvastatin 40mg for 6 weeks were assigned to 10/40 mg ezetimibe/simvastatin; 40 mg atorvastatin; 10 mg rosuvastatin (5 mg in elderly/Asian patients (in line with UK SPC)) between 27/03/2007 and 31/03/2008
| Milestone | Ezetimibe/Simvastatin | Atorvostatin | Rosuvastatin |
|---|---|---|---|
| Started | 261 | 263 | 262 |
| Completed | 249 | 252 | 251 |
| Not completed | 12 | 11 | 11 |
| Withdrew: Adverse event | 7 | 5 | 9 |
| Withdrew: Protocol violation | 0 | 2 | 1 |
| Withdrew: Withdrew consent | 3 | 3 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 |
| Withdrew: Discontinued after 41 days rx | 1 | 0 | 0 |
Fasting LDL-C was the primary efficacy variable. The primary efficacy analysis was based on the proportion of patients achieving a target of \<2mmol/l in fasting LDL-C at study end.
| Percent | Ezetimibe/Simvastatin | Atorvostatin | Rosuvastatin |
|---|---|---|---|
| Percentage of Patients Achieving a Target of Fasting LDL-C of <2mmol/l at Study End | 67.4 | 36.3 | 17.4 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ezetimibe/Simvastatin | — | — | — |
| Atorvostatin | — | — | — |
| Rosuvastatin | — | — | — |
| Event | Ezetimibe/Simvastatin | Atorvostatin | Rosuvastatin |
|---|---|---|---|
| Platelet count decreasedInvestigations | 1/259 | 0/260 | 0/261 |
| Aortic regurgitationCardiac disorders | 1/259 | 0/260 | 0/261 |
| Chest painGeneral disorders | 1/259 | 0/260 | 0/261 |
| Oesophageal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/259 | 0/260 | 0/261 |
| Erthematous rashSkin and subcutaneous tissue disorders | 0/259 | 1/260 | 0/261 |
| Areterial haemorrhageVascular disorders | 0/259 | 1/260 | 0/261 |
| Rectal bleedingGastrointestinal disorders | 0/259 | 0/260 | 1/261 |
| HydronephrosisRenal and urinary disorders | 0/259 | 0/260 | 1/261 |
| Bladder neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/259 | 0/260 | 1/261 |
| Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders | 0/259 | 0/260 | 1/261 |
| Event | Ezetimibe/Simvastatin | Atorvostatin | Rosuvastatin |
|---|---|---|---|
| DiarrheaGastrointestinal disorders | 6/259 | 1/260 | 8/261 |
| Age, Continuous(years) | Ezetimibe/Simvastatin | Atorvostatin | Rosuvastatin | Total |
|---|---|---|---|---|
| Mean | 64.7 ± 8.65 | 64.2 ± 8.44 | 63.9 ± 8.61 | 64.3 ± 8.56 |
| Age, Customized(participants) | Ezetimibe/Simvastatin | Atorvostatin | Rosuvastatin | Total |
|---|---|---|---|---|
| < 70 years | 185 | 187 | 195 | 567 |
| >=70 years | 76 | 76 | 67 | 219 |
| Sex: Female, Male(Participants) | Ezetimibe/Simvastatin | Atorvostatin | Rosuvastatin | Total |
|---|---|---|---|---|
| Female | 101 | 78 | 84 | 263 |
| Male | 160 | 185 | 178 | 523 |
| Race/Ethnicity, Customized(Participants) | Ezetimibe/Simvastatin | Atorvostatin | Rosuvastatin | Total |
|---|---|---|---|---|
| Asian | 3 | 0 | 2 | 5 |
| White | 254 | 261 | 257 | 772 |
| Black | 4 | 0 | 2 | 6 |
| Other | 0 | 2 | 1 | 3 |
No study locations are listed for this record.
Plan to share: No
The record gives a start of Mar 2007, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ezetimibe · Simvastatin